Performance of HALO Halozyme Therapeutics | 57.9% in 12m
Compare HALO with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Halozyme Therapeutics with its related Sector/Index XBI
Performance Duell HALO vs XBI
| TimeFrame | HALO | XBI |
|---|---|---|
| 1 Week | -7.27% | -4.68% |
| 1 Month | 14.0% | 2.20% |
| 3 Months | 15.1% | 4.12% |
| 6 Months | 42.0% | -3.48% |
| 12 Months | 57.9% | 22.61% |
| YTD | 58.4% | 7.10% |
| Rel. Perf. 1m | 0.83 | |
| Rel. Perf. 3m | 2.90 | |
| Rel. Perf. 6m | 3.71 | |
| Rel. Perf. 12m | 3.71 | |
| Spearman 1m | 0.65 | 0.47 |
| Spearman 3m | 0.92 | 0.70 |
Is Halozyme Therapeutics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Halozyme Therapeutics (NASDAQ:HALO) is currently (September 2024)
a good stock to buy. It has a ValueRay Fundamental Rating of 89.53 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HALO as of September 2024 is 65.87. This means that HALO is currently undervalued and has a potential upside of +11.25% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HALO as of September 2024 is 65.87. This means that HALO is currently undervalued and has a potential upside of +11.25% (Margin of Safety).
Is HALO a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
Values above 0%: HALO is performing better - Values below 0%: HALO is underperforming
Compare HALO with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.13% | 10.51% | 35.34% | 35.71% |
| US NASDAQ 100 | QQQ | -1.48% | 11.92% | 39.47% | 38.04% |
| US Dow Jones Industrial 30 | DIA | -4.45% | 10.20% | 36.72% | 39.39% |
| German DAX 40 | DBXD | -4.03% | 8.60% | 39.19% | 43.29% |
| UK FTSE 100 | ISFU | -5.02% | 7.73% | 29.70% | 39.73% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -4.59% | 16.31% | 48.29% | 68.80% |
| Hongkong Hang Seng | HSI | -5.05% | 9.23% | 41.51% | 63.73% |
| Japan Nikkei 225 | EXX7 | -0.15% | 8.32% | 52.15% | 52.03% |
| India NIFTY 50 | INDA | -5.17% | 11.39% | 33.58% | 33.58% |
| Brasil Bovespa | EWZ | -5.56% | 7.12% | 50.53% | 57.65% |
HALO Halozyme Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -3.20% | 13.41% | 34.65% | 33.37% |
| Consumer Discretionary | XLY | -4.75% | 8.61% | 40.03% | 51.80% |
| Consumer Staples | XLP | -7.85% | 7.93% | 30.20% | 39.74% |
| Energy | XLE | -1.50% | 15.12% | 41.70% | 60.03% |
| Financial | XLF | -4.10% | 7.28% | 32.12% | 27.15% |
| Health Care | XLV | -5.20% | 9.63% | 35.79% | 40.24% |
| Industrial | XLI | -3.03% | 10.85% | 37.81% | 36.82% |
| Materials | XLB | -2.61% | 12.41% | 39.92% | 46.24% |
| Real Estate | XLRE | -7.45% | 8.99% | 30.25% | 34.52% |
| Technology | XLK | 0.18% | 12.34% | 43.27% | 39.57% |
| Utilities | XLU | -6.77% | 9.83% | 19.90% | 34.13% |
| Aerospace & Defense | XAR | -2.06% | 10.00% | 37.55% | 31.55% |
| Biotech | XBI | -2.59% | 11.80% | 45.50% | 35.28% |
| Homebuilder | XHB | -2.87% | 10.58% | 34.18% | 20.29% |
| Retail | XRT | -2.29% | 14.51% | 45.27% | 39.24% |
Does Halozyme Therapeutics outperform its market, is HALO a Sector Leader?
Yes, over the last 12 months Halozyme Therapeutics (HALO) made 57.89%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months HALO made 15.10%, while XBI made 4.12%.
Yes, over the last 12 months Halozyme Therapeutics (HALO) made 57.89%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months HALO made 15.10%, while XBI made 4.12%.
| Period | HALO | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 14.00% | 2.20% | 3.49% |
| 3 Months | 15.10% | 4.12% | 1.39% |
| 12 Months | 57.89% | 22.61% | 22.18% |